QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 限定条件 内容类型：会议论文     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma 会议论文 作者:  Shi, Yuankai;  Dong, Mei;  Zhu, Jun;  Zhou, Daobin;  Huang, Huiqiang 收藏  |  浏览/下载：11/0  |  提交时间：2019/12/13 Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma 会议论文 BLOOD, 2015-12-03 作者:  Shi, Yuankai;  Dong, Mei;  Zhu, Jun;  Zhou, Daobin;  Huang, Huiqiang 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/13 Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study 会议论文 作者:  Robak, Tadeusz;  Huang, Huiqiang;  Jin, Jie;  Zhu, Jun;  Liu, Ting 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/19